Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Technology Scientific & Technical Instruments
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Ventripoint’s VMS+ technology with ASCEND’s Gen3EchoTM platf
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Comment by jopatcloon Dec 25, 2024 8:09am
19 Views
Post# 36377121

RE:RE:Ventripoint’s VMS+ technology with ASCEND’s Gen3EchoTM platf

RE:RE:Ventripoint’s VMS+ technology with ASCEND’s Gen3EchoTM platf
jopatclo wrote:
jopatclo wrote:
Interesting on Linkedin Hannah Crane BEM aime ceci 
 
Hannah Crane BEM aime ceci
Exciting news! Ventripoint Diagnostics Ltd. and ASCEND Cardiovascular have joined forces in an agreement to integrate Ventripoint’s VMS+ technology with ASCEND’s Gen3EchoTM platform. This collaboration combines two top-tier products, providing customers with a seamless and enhanced experience.
https://lnkd.in/d-NKFp2X
HealthcareInnovation Collaboration

Hannah Crane BEM aime ceci
Exciting news! Ventripoint Diagnostics Ltd. and ASCEND Cardiovascular have joined forces in an agreement to integrate Ventripoint’s VMS+ technology with ASCEND’s Gen3EchoTM platform. This collaboration combines two top-tier products, providing customers with a seamless and enhanced experience.
https://lnkd.in/d-NKFp2X
HealthcareInnovation Collaboration


Always positive, happy to have V4.0 for Europe and Canada in 2024. I really thought for 2024 the FDA V4.0! Now finally in 5 trading days before January 2, 2025. FDA V4.0 and Sales is coming & and almost everyone has a heart...Except Granhamf and these many fake accounts here and on ceo! & a few sheep followers to denigrate Ventripoint with their manipulative agenda to scare small investors.I also think that Dr. Adams the visionary with Ventripoint will silence the denigrators with FDA V4.0 & Sales very soon... 5 trading days before January 2, 2025Remember positive patience will be rewarded...& on post Matt Dobson ''Ventripoint Diagnostics Ltd. and ASCEND Cardiovascular have joined forces in an agreement to integrate Ventripoint’s VMS+ technology with ASCEND’s Gen3EchoTM platform.'' See On Ascend website https://ascendcv.com/ direct entry into 1500 major US centers.& Now CardioLogic Ltd: Introducing Ventripoint 4.0. Hugh is lining this up perfectly . This collaboration combines two top-tier products, providing customers with a seamless and enhanced experience. The BEST automation and analysis of the PLANET GEN3EHO & 1 Mayo Clinic #1 cardiac center in the entire world. #vpt,




Dario Freitas et Hannah Crane BEM aiment ceci
Exciting news! Ventripoint Diagnostics Ltd. and ASCEND Cardiovascular have joined forces in an agreement to integrate Ventripoint’s VMS+ technology with ASCEND’s Gen3EchoTM platform. This collaboration combines two top-tier products, providing customers with a seamless and enhanced experience.
https://lnkd.in/d-NKFp2X

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities